BSEChemcrux Enterprises LtdMediumNeutral
Announced Wed, 6 Aug · 14:48 IST

Increase in Authorised Share Capital and consequential amendment to MOA (in Capital Clause), subject to shareholders approval at the ensuing AGM

Corporate Actions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Chemcrux Enterprises' board approved increasing the authorised share capital from Rs. 15 crore to Rs. 20 crore (1.5 crore to 2 crore equity shares of Rs. 10 each), pending shareholder approval at the 29th AGM on September 24, 2025. The board also approved the ESOP 2025 scheme, allowing grant of up to 20 lakh stock options to eligible employees, including those in subsidiaries and group companies. Additionally, the board approved the unaudited Q1 FY26 results, appointed KSPS & Co LLP as secretarial auditor for 5 years, and approved continuation of three directors (Executive Chairman Girishkumar Shah, MD Sanjay Marathe, and Independent Director Bhanubhai Patel) past their respective retirement age thresholds. Mr. Ramesh Kambariya will step down as CFO effective end of business on August 11, 2025, citing personal career goals.

Likely market impact

The authorised capital hike and ESOP scheme are preparatory steps that give the company flexibility for future fund-raising or employee incentives but do not by themselves dilute existing shareholders. The CFO resignation is a management transition to watch, though no replacement has been announced yet.